CJC-1295 with DAC research overview

Compound identity and classification

CJC-1295 with DAC is classified as: Modified GHRH(1-29) analogue with drug affinity complex (DAC).

CJC-1295 with DAC is a synthetic analogue of the first 29 residues of growth hormone releasing hormone, modified with a maleimido drug affinity complex that binds serum albumin. Substitutions at positions associated with enzymatic cleavage are the structural feature distinguishing it from unmodified GHRH(1-29).

General research background

The compound appears in laboratory literature on growth hormone secretagogue chemistry, where the albumin-binding modification is studied as a way to extend the circulating half-life of a short-lived peptide in animal models. Reported work is preclinical and pharmacokinetic in character.

Molecular and biological pathways under investigation

Research models examine binding at the growth hormone releasing hormone receptor (GHRHR), a class B G protein-coupled receptor on somatotroph cells, and downstream cAMP/PKA signaling associated with growth hormone transcription and release.

Areas of laboratory research

Reported laboratory work with this material clusters into the following areas. Listing an area describes where research activity exists, not an established result.

• GHRH receptor binding and selectivity assays
• Pharmacokinetic and albumin-binding stability studies in animal models
• Somatotroph cell culture models of cAMP signaling
• Comparative studies against unmodified GHRH fragments

Analytical documentation

ATMI Labs publishes the identity and purity documentation supplied for each released lot. Any purity figure shown comes from the report filed for that specific batch rather than from a general catalog claim.

Research limitations

Published work involving CJC-1295 with DAC is largely confined to in vitro systems and preclinical animal models. Findings in those systems do not establish effects in humans, and model-to-model variability in preparation, vehicle, and endpoint selection limits direct comparison between studies.

Analytical purity describes the material, not biological activity. Laboratories should design their own controls, and treat any pathway description as a hypothesis under investigation rather than an established result.

Handling and laboratory considerations

Lyophilized research materials are handled as temperature-sensitive laboratory chemicals. Storage temperature, reconstitution solvent, container choice, and stability windows are determined by the receiving laboratory's written protocol.

Every ATMI Labs lot is released with batch documentation so identity and purity figures used in a study can be traced back to the specific lot in hand.

• Confirm the lot identifier on the vial label against the published quality record.
• Record lot, strength, and receipt date in the laboratory inventory before use.
• Follow institutional handling, labeling, and disposal procedures for research chemicals.

References and scientific sources

ATMI Labs does not summarize or reinterpret individual studies on this page. Laboratories designing work with this material are expected to consult the primary literature directly.

• PubMed / MEDLINE (National Library of Medicine) for peer-reviewed primary literature.
• PubChem and ChEMBL for chemical identity, structure, and physicochemical records.
• UniProt for sequence and receptor/target annotation where a protein target applies.
• The lot-specific quality record published by ATMI Labs for analytical identity and purity.

Research use scope

CJC-1295 with DAC supplied by ATMI Labs is sold exclusively for laboratory research and analytical purposes. It is not a drug, supplement, cosmetic, or food, and it is not intended for human or veterinary use.

Nothing on this page describes therapeutic use, dosing, or clinical outcomes. Literature referenced in general terms describes laboratory and preclinical model systems only.